Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.

Karen A. Kurdziel, William D. Figg, Jorge A. Carrasquillo, Susan Huebsch, Millie Whatley, David Sellers, Steven K. Libutti, James M. Pluda, William Dahut, Edward Reed, Stephen L. Bacharach

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.

Original languageEnglish (US)
Pages (from-to)86-93
Number of pages8
JournalMolecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
Volume5
Issue number2
StatePublished - Mar 2003
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Prostate-Specific Antigen
Positron-Emission Tomography
Androgens
Prostatic Neoplasms
Water
Blood Volume
Thalidomide
Physiologic Monitoring
Therapeutics
Carbon Monoxide
Tumor Burden
Neoplasms
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Radiology Nuclear Medicine and imaging

Cite this

Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. / Kurdziel, Karen A.; Figg, William D.; Carrasquillo, Jorge A.; Huebsch, Susan; Whatley, Millie; Sellers, David; Libutti, Steven K.; Pluda, James M.; Dahut, William; Reed, Edward; Bacharach, Stephen L.

In: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, Vol. 5, No. 2, 03.2003, p. 86-93.

Research output: Contribution to journalArticle

Kurdziel, KA, Figg, WD, Carrasquillo, JA, Huebsch, S, Whatley, M, Sellers, D, Libutti, SK, Pluda, JM, Dahut, W, Reed, E & Bacharach, SL 2003, 'Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.', Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, vol. 5, no. 2, pp. 86-93.
Kurdziel, Karen A. ; Figg, William D. ; Carrasquillo, Jorge A. ; Huebsch, Susan ; Whatley, Millie ; Sellers, David ; Libutti, Steven K. ; Pluda, James M. ; Dahut, William ; Reed, Edward ; Bacharach, Stephen L. / Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. In: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2003 ; Vol. 5, No. 2. pp. 86-93.
@article{02e5a62114284cbba7bc553d36808d79,
title = "Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.",
abstract = "PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta{\%}SUV(mean) (r=0.94, P<0.01) and Delta{\%}metabolic tumor volume (r=0.91, P<0.01) but less well with Delta{\%}blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.",
author = "Kurdziel, {Karen A.} and Figg, {William D.} and Carrasquillo, {Jorge A.} and Susan Huebsch and Millie Whatley and David Sellers and Libutti, {Steven K.} and Pluda, {James M.} and William Dahut and Edward Reed and Bacharach, {Stephen L.}",
year = "2003",
month = "3",
language = "English (US)",
volume = "5",
pages = "86--93",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.

AU - Kurdziel, Karen A.

AU - Figg, William D.

AU - Carrasquillo, Jorge A.

AU - Huebsch, Susan

AU - Whatley, Millie

AU - Sellers, David

AU - Libutti, Steven K.

AU - Pluda, James M.

AU - Dahut, William

AU - Reed, Edward

AU - Bacharach, Stephen L.

PY - 2003/3

Y1 - 2003/3

N2 - PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.

AB - PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.

UR - http://www.scopus.com/inward/record.url?scp=5444229812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444229812&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 86

EP - 93

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 2

ER -